Cerevel Therapeutics, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2018-01-01
- Employees
- -
- Market Cap
- $8.1B
- Website
- https://www.cerevel.com/
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 154
- Registration Number
- NCT04244175
- Locations
- ๐บ๐ธ
Miami, Florida, Miami, Florida, United States
๐บ๐ธPhiladelphia, Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธDowney, California, Downey, California, United States
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04241393
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Single Ascending Dose Trial of CVL-936 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT04232878
- Locations
- ๐บ๐ธ
Hassman Research Institute, Marlton, New Jersey, United States
Flexible-Dose Trial in Early Parkinson's Disease (PD)
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 304
- Registration Number
- NCT04223193
- Locations
- ๐ฆ๐บ
Macquarie Park, New South Wales, Sydney, New South Wales, Australia
๐บ๐ธFresno, California, Fresno, California, United States
๐บ๐ธBoca Raton, Florida, Boca Raton, Florida, United States
Fixed-Dose Trial in Early Parkinson's Disease (PD)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 522
- Registration Number
- NCT04201093
- Locations
- ๐บ๐ธ
Englewood, Colorado, Englewood, Colorado, United States
๐บ๐ธBoca Raton, Florida, Boca Raton, Florida, United States
๐บ๐ธScarborough, Maine, Scarborough, Maine, United States
A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT04136873
- Locations
- ๐บ๐ธ
Synergy San Diego, Lemon Grove, California, United States
๐บ๐ธCollaborative Neuroscience Network, LLC, Long Beach, California, United States
๐บ๐ธPillar Clinical Research, Bentonville, Arkansas, United States